Involved-node proton therapy in combined modality therapy for hodgkin lymphoma: Results of a phase 2 study

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 5, 2014, Pages 1053-1059

  Hoppe, Bradford S ^a   Flampouri, Stella ^a   Zaiden, Robert ^b   Slayton, William ^b   Sandler, Eric ^c   Ozdemir, Savas ^b   Dang, Nam H ^b   Lynch, James W ^b   Li, Zuofeng ^a   Morris, Christopher G ^a   Mendenhall, Nancy P ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOIDS; CHEMOTHERAPY; DIAGNOSIS; DISEASE CONTROL; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTON BEAMS; TOXICITY;

COMBINED MODALITY THERAPY; COMMON TERMINOLOGY CRITERIA; F-FLUORODEOXYGLUCOSE; METHODS AND MATERIALS; NONHEMATOLOGIC TOXICITY; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY;

PATIENT TREATMENT;

BLEOMYCIN; COBALT; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; LEVOTHYROXINE SODIUM; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; INSTITUTIONAL REVIEW; INVOLVED NODE PROTON THERAPY; LARGE CELL LYMPHOMA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PET-CT SCANNER; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON THERAPY; RADIATION DOSE; RECURRENCE FREE SURVIVAL; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHATIC IRRADIATION; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; ORGANS AT RISK; PROSPECTIVE STUDIES; PROTON THERAPY; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904152091     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.04.029     Document Type: Article

References (20)

1. S.L. Wolden, L. Chen, and K.M. Kelly et al. Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma - a report from the Children's Oncology Group J Clin Oncol 30 2012 3174 3180
2. A.E. Hay, B. Klimm, and B.E. Chen et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma Ann Oncol 24 2013 3065 3069
3. B.S. Hoppe, S. Flampouri, and Z. Su et al. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: Preliminary dosimetric outcomes from a phase II study Int J Radiat Oncol Biol Phys 83 2012 260 267
4. B.D. Hunter, S. Dhakal, and S. Voci et al. Pleural effusions in patients with Hodgkin lymphoma: Clinical predictors and associations with outcome Leuk Lymphoma 2014 in press
5. T. Girinsky, R. van der Maazen, and L. Specht et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines Radiother Oncol 79 2006 270 277
6. National Cancer Institute. Common Terminology Criteria for Adverse Events, v3.0 (CTCAE). 2006. Accessed at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
7. H.T. Eich, V. Diehl, and H. Gorgen et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial J Clin Oncol 28 2010 4199 4206
8. L.I. Gordon, F. Hong, and R.I. Fisher et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) J Clin Oncol 31 2013 684 691
9. L. Specht, J. Yahalom, and T. Illidge et al. Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG) Int J Radiat Oncol Biol Phys 2013 Jun 18 [Epub ahead of print]. http://dx.doi.org/10.1016/j.ijrobp.2013.05.005
10. J.O. Archambeau, G.W. Bennett, and S.T. Chen Potential of proton beams for total nodal irradiation Acta Radiol Ther Phys Biol 13 1974 393 401
11. M.V. Maraldo, N.P. Brodin, and M.C. Aznar et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Ann Oncol 24 2013 2113 2118
12. D.L. Andolino, T. Hoene, and L. Xiao et al. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients Int J Radiat Oncol Biol Phys 81 2011 e667 e671
13. B.S. Chera, C. Rodriguez, and C.G. Morris et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: Conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy Int J Radiat Oncol Biol Phys 75 2009 1173 1180
14. U. Schneider, A. Lomax, and N. Lombriser Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation Radiat Res 154 2000 382 388
15. M. Tukenova, C. Guibout, and M. Hawkins et al. Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood Int J Radiat Oncol Biol Phys 80 2011 339 346
16. S.C. Darby, M. Ewertz, and P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 368 2013 987 998
17. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Hodgkin's Lymphoma. v3.2011. 2011. Available at: http://www.nccn.org. Accessed December 13, 2012.
18. N.B. Figura, S. Flampouri, and K. Hopper et al. Consolidative proton therapy following high-dose chemotherapy and autologous stem cell transplant in an adolescent with relapsed Hodgkin lymphoma J Adolesc Young Adult Oncol 1 2011 103 106
19. A.Y. Minn, E. Riedel, and J. Halpern et al. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma Br J Haematol 159 2012 329 339
20. K.A. Goodman, E. Riedel, and V. Serrano et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma J Clin Oncol 26 2008 5240 5247